Volume 79, Issue 3, Pages (February 2011)

Slides:



Advertisements
Similar presentations
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Advertisements

Steven Fishbane, Jeffrey S. Berns, M.D.  Kidney International 
Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants  C.A. Solid,
A. Besarab  Kidney International  Volume 69, Pages S13-S18 (May 2006)
Iron status and iron supplementation in peritoneal dialysis patients
Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
Douglas S. Fuller, MS, Ronald L. Pisoni, PhD, MS, Brian A
Red blood cell life span and ‘erythropoietin resistance’
Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure  Steven Fishbane, Nobuyuki Miyawaki  Kidney International 
Volume 64, Pages S72-S77 (November 2003)
Volume 88, Issue 5, Pages (November 2015)
Volume 63, Issue 1, Pages (January 2003)
Rajiv Agarwal, John W. Kusek, Maria K. Pappas  Kidney International 
ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target  Szu-Chun Hung, Der-Cherng Tarng  Kidney International 
Volume 56, Issue 3, Pages (September 1999)
Volume 77, Issue 1, Pages 6-8 (January 2010)
Volume 54, Issue 2, Pages (August 1998)
Volume 84, Issue 3, Pages (September 2013)
Volume 87, Issue 1, Pages (January 2015)
Yasuhiro Hamada, Masafumi Fukagawa  Kidney International 
Volume 62, Issue 2, Pages (August 2002)
The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle  Douglas S. Fuller, MS, Ronald L. Pisoni,
Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns.
Volume 81, Issue 11, Pages (June 2012)
Comorbidity and confounding in end-stage renal disease
The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis  Sai Subhodhini Reddy, Jean L. Holley 
Volume 74, Issue 3, Pages (August 2008)
Darbepoetin alfa: A new therapeutic agent for renal anemia
Targets to retard the progression of diabetic nephropathy
Joseph W. Eschbach, John W. Adamson  Kidney International 
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Volume 77, Issue 2, Pages (January 2010)
Volume 82, Issue 5, Pages (September 2012)
Volume 87, Issue 2, Pages (February 2015)
Volume 92, Issue 2, Pages (August 2017)
Volume 64, Issue 5, Pages (November 2003)
Volume 67, Issue 3, Pages (March 2005)
Volume 85, Issue 1, Pages (January 2014)
Volume 65, Issue 6, Pages (June 2004)
Volume 78, Issue 2, Pages (July 2010)
Recent experience with high-dose intravenous iron administration
Günter Weiss, Florian Kronenberg  Kidney International 
Francesco Locatelli, Lucia Del Vecchio  Kidney International 
Volume 64, Pages S72-S77 (November 2003)
Volume 66, Issue 5, Pages (November 2004)
Extracorporeal therapy in sepsis: are we there yet?
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Volume 70, Issue 10, Pages (November 2006)
The value of ferric citrate, an iron-containing phosphate binder, might be different between Japan and the United States  Keitaro Yokoyama, Yukio Maruyama,
Volume 85, Issue 1, Pages 3-4 (January 2014)
Nephrology Crossword: Glomerulonephritis
Volume 67, Issue 6, Pages (June 2005)
Erythropoietin and iron
Volume 55, Issue 5, Pages (May 1999)
Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants  C.A. Solid,
Volume 63, Issue 6, Pages (June 2003)
Volume 65, Issue 6, Pages (June 2004)
Volume 66, Issue 6, Pages (December 2004)
Volume 63, Issue 3, Pages (March 2003)
Volume 57, Issue 2, Pages (October 2000)
Volume 62, Issue 6, Pages (December 2002)
Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation  A.K. Singh, D.W. Coyne,
Tobias Breidthardt, Alexandre Mebazaa, Christian E. Mueller 
Strategies for iron supplementation: Oral versus intravenous
Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga 
Mary B. Leonard, Lynn A. Donaldson, Martin Ho, Denis F. Geary 
Ronen Levi, Justin Silver  Kidney International 
Presentation transcript:

Volume 79, Issue 3, Pages 340-346 (February 2011) Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin  Takeshi Hasegawa, Jennifer L. Bragg-Gresham, Ronald L. Pisoni, Bruce M. Robinson, Shunichi Fukuhara, Takashi Akiba, Akira Saito, Kiyoshi Kurokawa, Tadao Akizawa  Kidney International  Volume 79, Issue 3, Pages 340-346 (February 2011) DOI: 10.1038/ki.2010.382 Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 1 Distributions of hemoglobin levels by cross-section. Intervals are <8, 8 to <9, 9 to <10, 10 to <11, 11 to <12, 12 to <13, and ≥13 g/dl. Kidney International 2011 79, 340-346DOI: (10.1038/ki.2010.382) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 2 Distributions of recombinant human erythropoietin (rHuEPO) doses by cross-section. Overall percentage of patients prescribed rHuEPO in January 2006 was 81.9% and in January 2007 was 82.2% (P=0.75). Among patients prescribed erythropoietin (EPO), the mean dose was 11.8% lower after bundling (P<0.001). The distribution of rHuEPO dose (as captured by the four categories in the figure) also differed between cross-sections (P<0.001). Kidney International 2011 79, 340-346DOI: (10.1038/ki.2010.382) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 3 Distributions of intravenous (IV) iron doses by cross-section. Overall percentage of patients prescribed IV iron in January 2006 was 31.8% and in January 2007 was 41.2% (P<0.001). Among patients prescribed IV iron, mean doses rose 6mg/month (P=0.15). The distribution of IV iron prescription (as captured by the five categories in the figure) also differed between cross sections (P<0.001). Kidney International 2011 79, 340-346DOI: (10.1038/ki.2010.382) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 4 Distributions of transferrin saturation (TSAT) by cross-section. Intervals are <10, 10 to <20, 20 to <30, 30 to <40, 40 to <50, and ≥50%. Kidney International 2011 79, 340-346DOI: (10.1038/ki.2010.382) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 5 Distributions of ferritin by cross-section. Intervals are <50, 50 to <100, 100 to <200, 200 to <300, 300 to <400, 400 to <500, and ≥500 ng/ml. Kidney International 2011 79, 340-346DOI: (10.1038/ki.2010.382) Copyright © 2011 International Society of Nephrology Terms and Conditions